An evaluation of motion compensation strategies and repeatability for abdominal 1H MR spectroscopy measurements in volunteer studies and clinical trials

NMR in Biomedicine

Volumn 25, Issue 6, 2012, Pages 859-865

  Germuska, M ^a   Tunariu, N ^a   Leach, M O ^a   Xu, Jian ^b   Payne, G S ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

Choline; Liver; Magnetic resonance spectroscopy; Motion correction; Tumours

Indexed keywords

ACCURATE MEASUREMENT; CANCER PATIENTS; CHOLINE; CHOLINE KINASE; CHOLINE-CONTAINING METABOLITES; CLINICAL TRIAL; COMPENSATION STRATEGY; DISEASE PROGRESSION; EXPECTED INTERVAL; FREQUENCY DISTORTION; HEALTHY TISSUES; LINE SHAPE; MOTION CORRECTION; MR SPECTROSCOPY; OFFLINE; PER UNIT; REPETITION TIME; REPRODUCIBILITIES; RESPIRATORY MOTIONS; SIGNALTONOISE RATIO (SNR); SUBSEQUENT REDUCTION;

DISEASES; LINEWIDTH; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MERGERS AND ACQUISITIONS; METABOLITES; RESPIRATORY MECHANICS; TUMORS;

MOTION COMPENSATION;

CHOLINE; WATER;

ABDOMINAL TUMOR; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; GATED IMAGING; HUMAN; HUMAN EXPERIMENT; LIVER; MOTION ANALYSIS SYSTEM; MOTION COMPENSATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; SIGNAL NOISE RATIO;

ABDOMINAL NEOPLASMS; ARTIFACTS; CHOLINE; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS; REPRODUCIBILITY OF RESULTS; RESPIRATORY-GATED IMAGING TECHNIQUES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84860634513     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1802     Document Type: Article

References (18)

1. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, Rosell R, Lacal J. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun. 2002; 296(3): 580-583.
2. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999; 59(13): 3112-3118.
3. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev. Mol. Diagn. 2006; 6(6): 821-829.
4. Chen CY, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, Hsu JS, Liu GC. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience. Radiology 2006; 239(2): 448-456.
5. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer 2001; 84(8): 1016-1022.
6. Helms G, Piringer A. Restoration of motion-related signal loss and line-shape deterioration of proton MR spectra using the residual water as intrinsic reference. Magn. Reson. Med. 2001; 46(2): 395-400.
7. Noworolski SM, Tien PC, Merriman R, Vigneron DB, Qayyum A. Respiratory motion-corrected proton magnetic resonance spectroscopy of the liver. Magn. Reson. Imaging 2009; 27(4): 570-576.
8. Lin JM, Tsai SY, Liu HS, Chung HW, Mulkern RV, Cheng CM, Yeh TC, Chen NK. Quantification of non-water-suppressed MR spectra with correction for motion-induced signal reduction. Magn. Reson. Med. 2009; 62(6): 1394-1403.
9. van der Meer RW, Doornbos J, Kozerke S, Schar M, Bax JJ, Hammer S, Smit JW, Romijn JA, Diamant M, Rijzewijk LJ, de Roos A, Lamb HJ. Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology 2007; 245(1): 251-257.
10. Star-Lack JM, Adalsteinsson E, Gold GE, Ikeda DM, Spielman DM. Motion correction and lipid suppression for 1H magnetic resonance spectroscopy. Magn. Reson. Med. 2000; 43(3): 325-330.
11. Kozerke S, Schar M, Lamb HJ, Boesiger P. Volume tracking cardiac 31P spectroscopy. Magn. Reson. Med. 2002; 48(2): 380-384.
12. Keating B, Deng W, Roddey JC, White N, Dale A, Stenger VA, Ernst T. Prospective motion correction for single-voxel 1H MR spectroscopy. Magn. Reson. Med. 2010; 64(3): 672-679.
13. Brown MA. Time-domain combination of MR spectroscopy data acquired using phased-array coils. Magn. Reson. Med. 2004; 52(5): 1207-1213.
14. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat. Methods Med. Res. 1999; 8(2): 135-160.
15. Ratiney H, Noworolski SM, Sdika M, Srinivasan R, Henry RG, Nelson SJ, Pelletier D. Estimation of metabolite T1 relaxation times using tissue specific analysis, signal averaging and bootstrapping from magnetic resonance spectroscopic imaging data. MAGMA 2007; 20(3): 143-155.
16. Keevil SF, Barbiroli B, Collins DJ, Danielsen ER, Hennig J, Henriksen O, Leach MO, Longo R, Lowry M, Moore C, Moser E, Segebarth C, Bovee W, Podo F. Quality assessment in in vivo NMR spectroscopy: IV. A multicentre trial of test objects and protocols for performance assessment in clinical NMR spectroscopy. Magn. Reson. Imaging 1995; 13(1): 139-157.
17. Rata M, Germuska M, Tunariu N, Giles S, Leach MO, deSouza N, Payne GS. Evaluation of Lipids in Extracranial Tumours using 1H MRS. ESMEMB Congress: Leipzig, Germany; 2011. 638.
18. Schwarz AJ, Maisey NR, Collins DJ, Cunningham D, Huddart R, Leach MO. Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br. J. Radiol. 2002; 75(900): 959-966.